July 16 (Reuters) - Thermo Fisher said on Wednesday it will buy Sanofi's

manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the

French drugmaker.

WHY IT'S IMPORTANT

Sanofi has been expanding its manufacturing presence in the U.S. market, following efforts

from peers such as Roche and Novartis, in a response to President Donald Trump's

repeated tariff threats on medicines.

Thermo also plans to increase its U.S. manufacturing investments in the range of about $2

billion to mitigate any tariff hit, the company said in April, the company said in April.

CONTEXT

Under the deal, Thermo will continue manufacturing a portfolio of therapies for Sanofi

after the acquisition.

The Ridgefield site operates as a sterile fill-finish and packaging facility with more

than 200 employees who will join Thermo Fisher.

BY THE NUMBERS

The companies did not disclose the financial terms of the deal. The transaction is expected

to close in the second half of 2025.

KEY QUOTE(S)

"Sanofi's Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling

us to better support our pharmaceutical and biotech customers with the critical production

capacity needed for essential medicines," said Marc Casper, CEO of Thermo Fisher.

WHAT'S NEXT

Thermo Fisher said it will strengthen its partnership with Sanofi while investing to expand

the Ridgefield site with additional manufacturing capacity.